RESEARCH PAPER

The Correlation of initial hematological feature with advanced stage in Chronic Lymphocytic Leukemia in Kurdistan Region of Iraq

Tavan Ismael Mahmood 1, Basil K. Abdulla2, Dana A. Abdullah3, Ahmed K. Yassin4, Kawa M. Hasan5 Zeki A. Mohamed 6, Nawsherwan S. Mohammed7, Hisham A. Getta8, Sana D. Jalal9, Rawand P. Shamoon10, Ranan Kardagh Polus11,Ghanim Salim Numan12, Bryar S. Rashid13, Zhala O. Ahmad14, Shokhan Mnustafa15, Shlan Salahaden Mohammed16, Lara Lateef Abdulrahman17, Marwa Nadhim Karam18, Rozh-hat A. yousif19.

1MBChB, KBMS-candidate, Department of Hematology, Hiwa Cancer hospital, Sulaymaniyah, Kurdistan Region, Iraq, tavan_esmaeel012@yahoo.com
2MBChB, FIMS-hematoo-oncology, Department of Hematology, Hiwa Cancer hospital, Sulaymaniyah, Kurdistan Region, Iraq, basilonc@yahoo.com
3MBChB, MSC, PhD hematopathology, Department of Pathology, College of Medicine, University of Sulaymaniyah, Sulaymaniyah, Kurdistan Region, Iraq, dr_dana73@hotmail.com
4MBChB, DM, CABM, FIBMS, FRCP, Department of Medicine, College of Medicine, Hawler Medical University, Erbil, Kurdistan Region, Iraq, mah_kawa@yahoo.com
5MBChB, FRCP, PhD, Department of Medicine, College of Medicine, Hawler Medical University, Erbil, Kurdistan Region, Iraq, mah_kawa@yahoo.com
6MBChB, MRCP, FIBMS, Department of Medicine, College of Medicine, University of Duhok, Duhok, Kurdistan Region, Iraq, barwar65@yahoo.com
7MBChB, FIBMS-path, Department of Pathology, College of Medicine, Hawler Medical University, Erbil, Kurdistan Region, Iraq, nawsherwan.sadiaq@med.hmu.edu.iq
8MBChB, FIBMS-path, Department of Pathology, College of Medicine, University of Sulaymaniyah, Sulaymaniyah, Kurdistan Region, Iraq, haalrawi@yahoo.com
9MBChB, FIBMS-path, FRCPath, Department of Pathology, College of Medicine, University of Sulaymaniyah, Sulaymaniyah, Kurdistan Region, Iraq, dr.sanjalal612@gmail.com
10MBChB, PhDhematopathology, Department of Pathology, College of Medicine, Hawler Medical University, Erbil, Kurdistan Region, Iraq, rawand.shamoon@med.hmu.edu.iq
11MBChB, FIBMS-path, FFCAP, Department of Pathology, College of Medicine, Hawler Medical University, Erbil, Kurdistan Region, Iraq, ranan.kardagh@hmu.edu.krd
12MBChB, FIBMS-path, Department of Hematology, Nanakali Hospital, Erbil, Kurdistan Region, Iraq, ghanem_59@yahoo.com
13MBChB, KBMS- Department of Hematology, Hiwa Cancer hospital, Sulaymaniyah, Kurdistan Region, Iraq, brvarsabah@gmail.com
14MBChB, KBMS-candidate, Department of Hematology, Hiwa Cancer hospital, Sulaymaniyah, Kurdistan Region, Iraq, zhala.ahamd@gmail.com
15MBChB, KBMS-candidate, Department of Hematology, Nanakali Hospital, Erbil, Kurdistan Region, Iraq, Shokhan.Mohammad@yahoo.com
16MBChB, KBMS-candidate, Department of Hematology, Nanakali Hospital, Erbil, Kurdistan Region, Iraq, shlan.mohammad@yahoo.com
17MBChB, KBMS-candidate, Department of Hematology, Nanakali Hospital, Erbil, Kurdistan Region, Iraq, lara2018lateef@gmail.com
18MBChB, KBMS-candidate, Department of Hematology, Nanakali Hospital, Erbil, Kurdistan Region, Iraq, marwanadhim@gmail.com
19MBChB, KBMS-candidate, Department of Hematology, Azadi Hospital, Duhok, Kurdistan Region, Iraq, rojhat.duhok1986@yahoo.com

* Corresponding Author:
Tavan Ismael Mahmood
E-mail:

Article History:
Received: 30/05/2021
Accepted: 28/07/2021
Published: 20/10/2021
Background and objective: Chronic lymphocytic leukemia (CLL) is considered by an accumulation of matured lymphocytes in the blood, bone marrow, spleen, and lymph nodes. We aimed to find the correlation of initial hematological feature with advanced stage in CLL. Methods: A retrospective study was conducted on 138 patients with CLL, confirmed by flow cytometry of peripheral blood collected in Hiwa Hematological and Oncological Hospital in Sulaimani, Nanakaly Hospital in Hawler, and Azadi Hematology- Oncology Center in Duhok, Kurdistan Region of Iraq dated from January 1, 2010, to December 31, 2020. Results: The mean age of 63.07±11 years with male predominance. The majority of patients at presentation were Rai Stage II and Binet stage A. The frequency of DAT positivity was found in (6.5%), which also established an appositive relationship with advanced stage, there were statistically significant relation of hemoglobin level, platelet counts, LDH level to Rai stage and Binet stage disease (P value <0.001), No association were noted between different age groups and initial laboratory finding, also no relation of gender to staging. Conclusion: In the present study there was a significant relation between laboratory findings (hemoglobin, platelet count, LDH levels) to with staging, in addition DAT positivity demonstrated a significant correlation with advanced stage, those with High LDH levels associated with more advanced Rai stage.

KEY WORDS: Chronic lymphocytic leukemia; Initial laboratory; advanced stage, KRI.
DOI: http://dx.doi.org/10.21271/ZJPAS.33.5.12
ZJPAS (2021), 33(5):105-115.

1.INTRODUCTION:

Chronic lymphocytic leukemia (CLL) is considered by the accretion of matured lymphocytes in the peripheral blood, bone marrow, spleen, and lymph nodes (Yun, Zhang and Wang, 2020). The diagnosis of CLL needs the presence of ≥5 × 10⁹/L B lymphocytes in the peripheral blood, continued for at least 3 months with clonality confirmed by flow cytometry according to International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria (Hallek et al., 2018) Also express CD19, CD5, and CD23 with weak or no expression of surface immunoglobulin (Ig), CD20, CD79b, and FMC7, CLL is the furthermore common leukemia of adults in the west nations, Most CLL patients in the over-all population are elderly (median age 71.5 years) (Yun, Zhang and Wang, 2020). The clinical presentation at diagnosis is very variable. About 60% of patients are asymptomatic, and the disease may be doubted after a routine complete blood count. While symptomatic, patients present with unclear symptoms of fatigue or weakness (Mercer, 2002). Patients generally have a good performance status at diagnosis, Lymphadenopathy with cervical and axillary lymph nodes bilaterally and symmetrically being affected, Splenomegaly is generally mild to moderate and is observed in nearly 50% of cases; hepatomegaly is less common, and rare at diagnosis, when the disease progresses, patients can have B symptoms (Rodrigues et al., 2016). Some of the chronic lymphocytic leukemia patients can presented with cytopenia’s. These contain autoimmune hemolytic anemia, immune thrombocytopenic purpura, pure red cell aplasia and autoimmune agranulocytosis. Between CLL associated cytopenia’s, autoimmune hemolytic anemia (AIHA) is the greatest common and considered by a positive direct antiglobulin test (DAT), known as Direct Coombs test with elevated serum bilirubin, increased reticulocytes and presence of spherocytosis on peripheral blood film examination (Haider et al., 2019). AIHA is generally detected in advanced stages of disease and associated with poor prognostic group, DAT status at the time of disease appearance shows new prognostic indicator for overall survival (Abbas et al., 2015). Assessment of such patients should include a complete blood count with differential; flow cytometry of the peripheral blood to define the immunophenotype of circulating lymphocytes; and check of the peripheral smear, however Assessment of the bone marrow is not usually required, but should be examined in those patients with unexplained cytopenia’s (Kanti RR, Stilgenbauer S and Aster JC, 2019). The serological test in CLL, is standard and consist of Lymphocyte doubling time (LDT), serum beta2-microglobulin (s-β2M), serum thymidine kinase (s-TK) and lactic dehydrogenase (LDH) are the greatest common straight serum markers in CLL and expect poor results. LDT ≤ 12 months expects poor prognosis while LDT > 12 months associates with an extended treatment-free period and survive. LDT is an pointer of time to first treatment (TTFT) and related with shorter PFS, overall survival (OS) and Richter’s transformation. It is still of prognostic value in patients with trisomy 12 (Rosenquist et al., 2021).
it is commonly understood as reflecting high tumor burden or tumor aggressiveness and conveys a poor prognosis in CLL (Sagatys and Zhang, 2012).

The Rai and Binet clinical staging systems are useful to stratify patients, describing their risk and prognosis (Hallek et al., 2018).

Administration protocol for treatment of CLL consist of combination of immunotherapy and standard chemotherapy for patients with symptomatic, advanced or progressive disease. While for patients with stable disease the “watch and wait” algorithm is usually deployed (Hallek et al., 2018). (Madu et al., 2019).

2. Materials and Methods:

2.1. Study design and patients

The present study was a retrospective observational study that involved 138 patients who had CLL were enrolled. The patients were admitted to Hiwa Hematological and Oncological Hospital in Sulaimani, Nanakaly Hospital in Hawler, and Azadi Hematology Oncology Center in Duhok, Kurdistan Region Iraq, from January 1, 2010, to December 31, 2020.

Patients involved in this study were established according to the International workshop on chronic lymphocytic leukemia (IWCLL) (Hallek et al., 2018).

The inclusion criteria included all patients who had been diagnosed with CLL, (both gender male and female, age more than 35 years, newly diagnosis, and all races.)

Exclusion criteria all patients with
1- incomplete data
2- Age younger than 35 years
3- Transformation of cases during data collection,
4- Small Lymphocytic Lymphoma
5- Hairy Cells Leukemia and others B-Cells Lymphoma.

The documented data about the patients was collected from the electronic databases of the mentioned hospitals, the demographic features containing (age, gender, race, residency, occupation, BMI) , presenting features(anemia, fatigue, B-symptoms, lump), hematological panel (complete blood count, blood film, coombs test, retic count, blood group) , biochemical panel(lactate dehydrogenase), organomegaly ,peripheral lymphadenopathy confirmed with ultrasound and flow cytometry of peripheral blood was used to confirm the diagnosis but molecular and cytogenetic studies were not done as it was not available.

Then we classified our patients according to Rai and Binet staging system (Hallek et al., 2018). Also the patients were treated, followed up and assessed their response according to International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria (Hallek et al., 2018), some patients with a symptomatic early stage disease(Rai 0, Binet A) monitored without therapy, but patients with intermediate –risk and high-risk disease generally received treatment with chemo-immunotherapy and targeting therapy, and assessment of their response at least 2 months after completion of therapy.

2.2. Statistical analysis:

After data collection and prior to data entry and analysis, the questions of study were coded. Data entry performed via using an excel spreadsheet then the statistical analysis was performed by SPSS program, version 21 (IBM SPSS Statistical Package for the Social Sciences). The data presented in tabular forms showing the frequency and relative frequency distribution of different variables. Chi-square test used to compare different qualitative (categorical) variables of the study (to find their association) as comparing different laboratory finding with age groups, sex and the two types of staging (Benit and Modified Rai). Different types of Bar charts and Pie charts as well as arithmetic scale line graphs were used to describe some variables of the study diagrammatically.

2.3. Ethical consideration:

Research Ethical Committee of the Kurdistan Board of Medical Specialties (KBMS) and Cancer Center accepted the study proposal.

3. Results

This study comprised 138 patients with CLL, the mean age of 63.07±11, 29 cases are female and 71 patients are male (ranged from 35 to ≥80 years). The major age group was in 50-64 years with 42.8 %. And male: female ratio is 2.45:1, as shown in (Table 1)
The majority of patients at presentation were Rai Stage II (44 cases, 31.9%), Binet stage A (58 cases, 42.0%) while minimum number of them had Rai Stage III (13 cases, 9.4%), Binet stage B (33 cases, 23.9%) as shown mentioned (Table 2). The direct anti-globin test positivity was set up in (9 cases, 6.5%), negativity (129 cases 93%). LDH was measured in all patients, it was normal in 52.9 %( n=73) and in 47.1 % (n=65) was above the normal, the others hematological markers are shown in (Table 3).

The relation between different age groups and initial laboratory finding is statistically not significant (P >0.05) as shown in (Table 4). Regarding the relation of the same age grouping to the staging systems of CLL, It was obvious that there was a highly significant correlation between age and Rai stage of presentation, with majority of patients of Stage II (P value 0.04), but correlation of age with Binet stage and modified Rai staging of presentation are also statistically not significant (P value> 0.05) as shown in table (Table 5).

Regarding the relationship of laboratory finding to the staging of presentation, there are statistically a significant relation of hemoglobin level, platelet counts, LDH level to Rai stage and Binet stage disease (P value <0.001), but relation of lymphocyte groups, coombs test, Blood groups of patients to Rai stage and Binet stage are statistically not significant(P value > 0.05) (Table 6).

We also want to discovery any relation between gender of patients and CLL staging systems in (Table 7), we found that more female patients have Rai Stage 0 and Binet stage A disease, while more male patients have Rai Stage II and Binet stage A disease, and both male and female have Modified intermediate risk, but again this relation is also statistically not significant (P value> 0.05).

| Age | Frequency | Percent |
|-----|-----------|---------|
| 35 - 49 Years | 22 | 15.9% |
| 50 - 64 years | 59 | 42.8% |
| 65 - 79 years | 47 | 34.1% |
| ≥ 80 years | 10 | 7.2% |
| Total | 138 | 100.0% |

| Staging category | Frequency | Percentage |
|------------------|-----------|------------|
| Rai 0 | 30 | 21.7% |
| Rai I | 15 | 10.9% |
| Rai II | 44 | 31.9% |
| Rai III | 13 | 9.4% |
| Rai IV | 36 | 26.1% |
| Binet A | 58 | 42.0% |
| Binet B | 33 | 23.9% |
| Binet C | 47 | 34.1% |
| Modified Rai Low risk | 30 | 21.7% |
| Modified Rai Intermediate risk | 59 | 42.8% |
| Modified Rai High risk | 49 | 35.5% |

Table (1): Age distribution of chronic lymphocytic leukemia in KRI

Table (2): Staging systems of chronic lymphocytic leukemia patients:
Table (3): Initial laboratory finding of CLL patients

| Laboratory test      | Frequency | Percentage |
|----------------------|-----------|------------|
| Hemoglobin ≤ 10      | 31        | 22.5%      |
|                      | > 10      | 107        | 77.5%      |
| Platelet level ≥ 100 | 104       | 75.4%      |
|                      | < 100     | 34         | 24.6%      |
| Lymphocyte groups 5-10| 81        | 58.7%      |
|                      | 10.1-50   | 36         | 26.1%      |
|                      | > 50      | 21         | 15.2%      |
| LDH                  |           |            |
| Normal Normal (≤ 280| 31        | 52.9%      |
| U/L                  |           |            |
| High (> 280 U/L)     | 65        | 47.1%      |
| Coomb's test         |           |            |
| Positive             | 9         | 6.5%       |
| Negative             | 129       | 93.5%      |
| Blood group A + ve   | 28        | 29.8%      |
|                      | B + ve    | 23         | 24.5%      |
|                      | B - ve    | 1          | 1.1%       |
|                      | AB + ve   | 5          | 5.3%       |
|                      | AB - ve   | 1          | 1.1%       |
|                      | O + ve    | 33         | 35.1%      |
|                      | O - ve    | 3          | 3.2%       |

Table (4): Relation between age distribution of CLL patients and initial laboratory finding

| Laboratory test      | 35 - 49 Y | 50 - 64 Y | 65 - 79 Y | ≥ 80 Y | Total | P value |
|----------------------|-----------|-----------|-----------|--------|-------|---------|
| Hemoglobin ≤ 10      | 4         | 12        | 11        | 4      | 31    | 0.54    |
|                      | 18        | 47        | 36        | 6      | 107   |         |
| Platelet level ≥ 100 | 15        | 43        | 39        | 7      | 104   | 0.49    |
|                      | 7         | 16        | 8         | 3      | 34    |         |
| Lymphocyte groups 5-10| 13        | 30        | 31        | 7      | 81    | 0.75    |
|                      | 6         | 19        | 9         | 2      | 36    |         |
|                      | 3         | 10        | 7         | 1      | 21    |         |
| LDH                  | 7         | 22        | 16        | 5      | 50    | 0.93    |
Table (5): correlation between age distributions of CLL patients with staging systems

| Staging         | 35 - 49 Y | 50 - 64 Y | 65 – 79 Y | ≥ 80 Y | Total | P value |
|-----------------|-----------|-----------|-----------|--------|-------|---------|
| Rai staging     |           |           |           |        |       |         |
| 0               | 1         | 11        | 15        | 3      | 30    | 0.04    |
| I               | 6         | 8         | 1         | 0      | 15    |         |
| II              | 5         | 19        | 18        | 2      | 44    |         |
| III             | 2         | 4         | 5         | 2      | 13    |         |
| IV              | 8         | 17        | 8         | 3      | 36    |         |
| Binet staging   |           |           |           |        |       |         |
| A               | 9         | 24        | 21        | 4      | 58    | 0.52    |
| B               | 3         | 15        | 14        | 1      | 33    |         |
| C               | 10        | 20        | 12        | 5      | 47    |         |
| Modified Rai staging | | | | | |
| Low risk        | 1         | 11        | 15        | 3      | 30    | 0.15    |
| Intermediate risk | 11     | 27        | 19        | 2      | 59    |         |
| High risk       | 10        | 21        | 13        | 5      | 49    |         |
Table (6): correlation between laboratory findings of CLL patients with staging systems

| Lab. Finding / Rai Staging | Modified Rai staging | Total | P value |
|---------------------------|----------------------|-------|---------|
|                           | Low risk             | Intermediate risk | High risk |       |
| Hemoglobin                |                      |                   |           |       |
| ≤ 10                      | 0 (0%)               | 0 (0%)           | 31 (100%) | < 0.001|
| > 10                      | 30 (28.0%)           | 59 (55.1%)       | 18 (16.8%)|       |
| Platelet level            |                      |                   |           |       |
| ≥ 100                     | 30 (28.8%)           | 59 (56.7%)       | 15 (14.5%)| < 0.001|
| < 100                     | 0 (0%)               | 0 (0%)           | 34 (100%) |       |
| Lymphocyte groups         |                      |                   |           |       |
| 5 – 10                    | 21 (26%)             | 30 (37%)         | 30 (37%)  | 0.06   |
| 10.1 – 50                 | 9 (25%)              | 18 (50%)         | 9 (25%)   |       |
| > 50                      | 0 (0%)               | 11 (52.4%)       | 10 (47.6%)|       |
| LDH                       |                      |                   |           |       |
| Normal (≤ 280 U/L)        | 19 (26.0%)           | 25 (34.2%)       | 29 (39.7%)| 0.09   |
| High (> 280 U/L)          | 11 (16.9%)           | 34 (52.3%)       | 20 (30.8%)|       |
| Coomb's test              |                      |                   |           |       |
| Positive                  | 2 (22.2%)            | 2 (22.2%)        | 5 (55.6%) | 0.36   |
| Negative                  | 28 (21.7%)           | 57 (44.2%)       | 44 (34.1%)|       |
| Blood group               |                      |                   |           |       |
| A+                        | 7 (25%)              | 12 (42.9%)       | 9 (32.1%) | 0.70   |
| B+                        | 2 (8.7%)             | 9 (39.1%)        | 12 (52.2%)|       |
| B-                        | 0 (0%)               | 1 (100%)         | 0 (0%)    |       |
| AB+                       | 1 (20%)              | 3 (60%)          | 1 (20%)   |       |
| AB-                       | 0 (0%)               | 1 (100%)         | 0 (0%)    |       |
| O+                        | 8 (24.2%)            | 15 (45.5%)       | 10 (30.3%)|       |
| O-                        | 0 (0%)               | 1 (33.3%)        | 2 (66.7%) |       |

| Lab. Finding / Benit Staging | A | B | C | Total | P value |
|-----------------------------|---|---|---|-------|---------|
| Hemoglobin                  | 0 (0%) | 0 (0%) | 31 (100%) | 31 (100%) | < 0.001 |
| ≤ 10                         | 58 | 33 (30.8%) | 16 (15.0%) | 107 (100%) |       |
| > 10                         | 58 | 33 (31.7%) | 13 (12.5%) | 104 (100%) | < 0.001 |
| Platelet level               | 0 (0%) | 0 (0%) | 34 (100%) | 34 (100%) |       |
Table (7): correlation between gender distributions of patients with staging

| Lymphocyte groups | 5 – 10 | 10.1 – 50 | > 50 |
|-------------------|--------|-----------|------|
|                   | 35 (43.2%) | 18 (22.2%) | 28 (34.6%) | 81 (100%) | 0.16 |
|                   | 19 (52.8%) | 8 (22.2%)  | 9 (25%)  | 36 (100%) |
|                   | 4 (19%)   | 7 (33.3%) | 10 (47.6%) | 21 (100%) |

| LDH               | Normal (≤ 280 U/L) | 32 (43.8%) | 14 (19.2%) | 27 (37.0%) | 73 (100%) | < 0.001 |
|                   | High (> 280 U/L)   | 26 (40%)   | 19 (29.2%) | 20 (30.8%) | 65 (100%) |         |

| Coomb's test      | Positive | 3 (33.3%) | 1 (11.1%) | 5 (55.6%) | 9 (100%) | 0.34 |
|                   | Negative | 55 (52.6%) | 32 (24.8%) | 42 (32.6%) | (100%)   |       |

| Blood group       | A+       | 10 (35.7%) | 10 (35.7%) | 8 (28.6%) | 28 (100%) | 0.47 |
|                   | B+       | 6 (26.1%)  | 6 (26.1%)  | 11 (47.8%) | 23 (100%) |       |
|                   | B-       | 0 (0%)     | 1 (100%)   | 0 (0%)    | 1 (100%)  |       |
|                   | AB+      | 3 (60%)    | 1 (20%)    | 1 (20%)   | 5 (100%)  |       |
|                   | AB-      | 0 (0%)     | 1 (100%)   | 0 (0%)    | 1 (100%)  |       |
|                   | O+       | 15 (45.5%) | 8 (24.2%)  | 10 (30.3%) | 33 (100%) |       |
|                   | O-       | 1 (33.3%)  | 0 (0%)     | 2 (66.7%) | 3 (100%)  |       |

| Benit staging     |         |           |       |       |       |

| Gender/ Staging   | Male | Female | Total | P value |
|-------------------|------|--------|-------|---------|
| Rai staging       |      |        |       |         |
| 0                 | 18   | 12     | 30    | 0.18    |
| I                 | 9    | 6      | 15    |         |
| II                | 33   | 11     | 44    |         |
| III               | 8    | 5      | 13    |         |
| IV                | 30   | 6      | 36    |         |
| Benit staging     |      |        |       |         |
| A                 | 38   | 20     | 58    | 0.45    |
| B                 | 24   | 9      | 33    |         |
| C                 | 36   | 11     | 47    |         |
| Modified RAI      |      |        |       |         |
| staging           |      |        |       |         |
| Low risk          | 18   | 12     | 30    | 0.25    |
4. Discussion

CLL is the greatest common form of adult leukemia in the Western countries, through maximum of cases in elders above 50 (Basabaeen et al., 2019).

We retrospectively collected 138 patients, the mean age of presentation was 63.1 years old (ranged from 35 to ≥80 years) which are nearby to the results reported in other Iraq studies (Hasan, 2018), (Al-rubaie and Mohammed, 2018), also comparable to the result described in Iran (Payandeh, Sadeghi and Sadeghi, 2015), while the results show a decade younger than US (Brander et al., 2017), (Pulte et al., 2016). This difference can be qualified to the variance in population structure, residence, genetic tendency, environmental factor, disproportion in lifetime expectation and sample size among Iraq and western countries.

In our study the male to female ratio 2.45:1 which was comparable to that of western countries and other world studies (Brander et al., 2017) (Pulte et al., 2016), (Basabaeen et al., 2019), (Abbas et al., 2015). But it was higher than that described by other Iraqi studies (Al-rubaie and Mohammed, 2018), this may also due to variance in sample size. But in very studies clear finding of male predominance was stable. Which might be linked to genetic bases as revealed by results described by Cantu ES, McGill JR et al (Cantú et al., 2013).

In the current study, most patient presented at Rai stage II (31.9%) or Binet stage A (42%) or modified Rai intermediate risk (42.8%), according to the data from other western world such as in Brazil and USA are frequently primary seen in Rai stage II (35.6%), Modified Rai intermediate risk (43.2%) and Rai stage II (37.9%), Binet stage A (42.6%) respectively (Faria et al., 2000), (Pflug et al., 2014). But according to the data from previous study of Iraq most of patients existing at an advance stage such as Rai stage III or IV (59.1%) Binet stage C (55.2%) (Hasan, 2018), (Naji, 2012), also in Iran greatest patient is realized in advanced stage (38.5%) which are various in present study (Payandeh, Sadeghi and Sadeghi, 2015) may be due to regular review, services now available for initial recognition and diagnosis of the disease.

We tried to find any relation among staging and their gender but statistically it was not significant while both male and female mostly have modified Rai intermediate Risk and Binet stage A disease.

In current study in relation of age to staging our study showed that advance stage is more common in age 50-64 years which was similar to the preceding study done in Iraq (Naji, 2012). also in USA (Parikh et al., 2014).

Also, male was more frequently affected by the disease than female which is similar to a study done in Iran (Payandeh, Sadeghi and Sadeghi, 2015).

We found that in 138 patients, 44 patient blood group was not done (31.95%), majority of our patients have O-positive blood group (33 cases 35.1%) ; we didn’t find any connection between blood group and staging in current study, and this may necessity further researches as we could not find any research about ABO blood grouping in CLL, except one paper speaking about the spreading of ABO blood type in patients with leukemia which displays that in CLL patients majority have blood Group O (Ochoa-garcía et al., 2019).

The occurrence positive DAT in current study was (6.5%), Inadequate studies are available from Asian countries, Before only study showed in Erbil city of Iraq has reported 11% of CLL patients showing DAT positivity and its associated with significant anemia, this outcome was higher to that of our study (Hasan, 2018). Various studies conducted in United State, Spain, England and have re-counted a frequency of positive DAT in 4.5%, 4.3% and 7.7% of CLL patients respectively However, the prevalence of DAT positivity in our patients appears to be more than in US, Spain, and less than in England these studies conducted in western world (Kyasa et al., 2003) (Moreno et al., 2010) (Ward, 2001).

In this study on 138 CLL patients at diagnosis, DAT positive result was associated with more advanced stage, less predominant in stage A disease, as it was testified to another study in Iraq.

| Intermediate risk | 42 | 17 | 59 |
|-------------------|----|----|----|
| High risk         | 38 | 11 | 49 |
| Total             | 98 | 40 | 138 |
Asian and America(Hasan, 2018)‘(Abbas et al., 2015)‘(Dearden et al., 2008).
In current study we found that LDH has statistically significant relation with staging (p-value<0.001) which was comparable to that reported by Asian, Germany and Italy studies(Li et al., 2017)‘(Pflug et al., 2014)‘(Autore et al., 2019).
Since LDH is an low-priced and usually performed laboratory parameter, also reflect tumor burden and such disease activity, we found that 73(52.9%) patients displayed levels within normal range, and 65(47.1%) patients exhibited elevated LDH levels, in compare elevated LDH levels to previous study in Iraq and Asian was lower (82.9%, 70%) respectively,(Hasan, 2018)‘(Al-rubai and Mohammed, 2018)‘(Mozaheb, NazarAbadi and Aghaee, 2012) but in compare to Germany study in current study the elevated LDH level was more than in Germany study (47.1% versus 34.8%) (Pflug et al., 2014).
In current study Those with high LDH level showed (52.3%, 30.8%) associated with intermediate and high risk of modified Rai staging respectively and 40% with Binet Stage A, this was an arrangement to conducted study in Italy (Autore et al., 2019).

5. Conclusion:
The median age was similar to that observed in Iraq and Iran. Male –to-female ratio which was comparable to that of western countries and other world studied with male predominance which was obvious in all studies; however, patients more frequently presented at early stage comparable to the western population. And DAT positivity in our setting appears relatively similar to international studies, also an association of positive DAT was found with advanced stage like regional and western studies. Also there was statistically significant relation between laboratory finding to the staging (including hemoglobin, platelet count and LDH levels) similar to the regional and international studies, those with High LDH levels associated with advanced Rai stage.

Acknowledgment
We wish to extend our special thanks to the Smart Health Tower Research Center for their assistance.

Reference:
Abbas, S. A. et al. (2015) ‘Direct coombs test positivity in B-chronic lymphoid leukemia: A marker of advanced clinical disease’, Asian Pacific Journal of Cancer Prevention, 16(14), pp. 6007–6010. doi: 10.7314/AJPJP.2015.16.14.6007.
Al-rubai, H. A. and Mohammed, S. J. (2018) ‘Assessment of Interleukin-8 in Patients with Chronic Lymphocytic Leukemia in Correlation with the Prognostic Factors : β2 -microglobulin , LDH and Binet Stage’, 17(2).
Autore, F. et al. (2019) ‘Elevated lactate dehydrogenase has prognostic relevance in treatment-naive patients affected by chronic lymphocytic leukemia with trisomy 12’, Cancers, 11(7), pp. 1–12. doi: 10.3390/cancers11070896.
Basabaeen, A. A. et al. (2019) ‘Clinical presentation and hematological profile among young and old chronic lymphocytic leukemia patients in Sudan’, BMC Research Notes, 12(1), pp. 12–17. doi: 10.1186/s13104-019-4239-7.
Brander, D. M. et al. (2017) ‘Welcome & Introductions Living with Chronic Lymphocytic Leukemia ( CLL )’, (Cll), pp. 1–43.
Cantú, E. S. et al. (2013) ‘Male-to-female sex ratios of abnormalities detected by fluorescence in situ hybridization in a population of chronic lymphocytic leukemia patients’, Hematology Reports, 5(1), pp. 13–17. doi: 10.4081/hr.2013.e4.
Dearden, C. et al. (2008) ‘The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: A beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia’, Blood, 111(4), pp. 1820–1826. doi: 10.1182/blood-2007-07-101303.
Faria, J. R. de et al. (2000) ‘Prognosis related to staging systems for chronic lymphocytic leukemia’, Sao Paulo Medical Journal, 118(4), pp. 83–88. doi: 10.1590/s1516-31802000000400002.
Haider, M. S. et al. (2019) ‘Autoimmune cytophenias in chronic lymphocytic leukemia’, Pakistan Journal of Medical Sciences, 35(5), pp. 1334–1338. doi: 10.12669/pjms.35.5.369.
Hallek, M. et al. (2018) ‘iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL’, Blood, 131(25), pp. 2745–2760. doi: 10.1182/blood-2017-09-806398.
Hasan, K. M. (2018) ‘Clinical aspects, immunophenotypic analysis and survival rate of chronic lymphocytic leukaemia patients in Erbil city, Iraq’, Sultan Qaboos University Medical Journal, 18(4), pp. e461–e467. doi: 10.18295/squmj.2018.18.04.006.
Kanti RR, Stilgenbauer S and Aster JC (2019) ‘Clinical features and diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma - UpToDate [Internet] Updated May 2019’, pp. 1–36. Available at: https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-chronic-lymphocytic-
leukemia-small-lymphocytic-lymphoma.

Kyasa, M. J. et al. (2003) ‘Autoimmune cytopenia does not predict poor prognosis in chronic lymphocytic leukemia/small lymphocytic lymphoma’, *American Journal of Hematology*, 74(1), pp. 1–8. doi: 10.1002/ajh.10369.

Li, H. et al. (2017) ‘Serum LDH level may predict outcome of chronic lymphocytic leukemia patients with a 17p deletion: A retrospective analysis of prognostic factors in China’, *Chinese Journal of Cancer Research*, 29(2), pp. 156–165. doi: 10.21147/j.issn.1000-9604.2017.02.09.

Madu, A. J. et al. (2019) ‘Presenting features and treatment outcomes of chronic lymphocytic leukaemia in a resource poor Southern Nigeria’, *Malawi Medical Journal*, 31(2), pp. 144–149. doi: 10.4314/mmj.v31i2.7.

Mercer, R. (2002) ‘Review articles’, *The Antiquaries Journal*, 82, pp. 358–365. doi: 10.1017/S000358150007390X.

Moreno, C. et al. (2010) ‘Autoimmune cytopenia in chronic lymphocytic leukemia: Prevalence, clinical associations, and prognostic significance’, *Blood*, 116(23), pp. 4771–4776. doi: 10.1182/blood-2010-05-286500.

Mozaheb, Z., NazarAbadi, M. H. H. and Aghaee, M. A. (2012) ‘Chronic lymphocytic leukemia and prognostic factors’, *Asian Pacific Journal of Cancer Prevention*, 13(7), pp. 3009–3013. doi: 10.7314/APJCP.2012.13.7.3009.

Naji, A. S. (2012) ‘Outcome of 49 Iraqi adult patients with Chronic Lymphocytic Leukemia treated with oral alkylating agent’. * مجلة كلية الطب (٥٠)٢(٠٢), pp. 126–130. doi: 10.32007/jfacmedbagdad.v2126-130.

Ochoa-garcía, P. P. et al. (2019) ‘Association between the phenotype of the blood group system AB0 and’, 30(4), pp. 639–644.

Parikh, S. A. et al. (2014) ‘Chronic lymphocytic leukemia in young (≤ 55 years) patients: A comprehensive analysis of prognostic factors and outcomes’, *Haematologica*, 99(1), pp. 140–147. doi: 10.3324/haematol.2013.086066.

Payandeh, M., Sadeghi, E. and Sadeghi, M. (2015) ‘Survival and clinical aspects for patients with chronic lymphocytic leukemia in Kermanshah, Iran’, *Asian Pacific Journal of Cancer Prevention*, 16(17), pp. 7987–7990. doi: 10.7314/APJCP.2015.16.17.7987.

Pflug, N. et al. (2014) ‘Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia’, *Blood*, 124(1), pp. 49–62. doi: 10.1182/blood-2014-02-556399.

Pulte, D. et al. (2016) ‘Trends in survival of chronic lymphocytic leukemia patients in Germany and the USA in the first decade of the twenty-first century’, *Journal of Hematology and Oncology*, 9(1), pp. 1–8. doi: 10.1186/s13045-016-0257-2.

Rodrigues, C. A. et al. (2016) ‘Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia’, *Revista Brasileira de Hematologia e Hemoterapia*, 38(4), pp. 346–357. doi: 10.1016/j.bjhh.2016.07.004.

Rosenquist, R. et al. (2013) ‘Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: Where do we stand?’, *Leukemia and Lymphoma*, 54(11), pp. 2351–2364. doi: 10.3109/10428194.2013.783913.

Sagatys, E. M. and Zhang, L. (2012) ‘Clinical and laboratory prognostic indicators in chronic lymphocytic leukemia’, *Cancer Control*, 19(1), pp. 18–25. doi: 10.1177/107327481201900103.

Ward, J. H. (2001) ‘Autoimmunity in chronic lymphocytic leukemia.’, *Current treatment options in oncology*, 2(3), pp. 253–257. doi: 10.1007/s11864-001-0039-z.

Yun, X., Zhang, Y. and Wang, X. (2020) ‘Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia’, *Biomarker Research*, 8(1), pp. 1–11. doi: 10.1186/s40364-020-00222-3.